PINTON, GIULIA
 Distribuzione geografica
Continente #
EU - Europa 730
NA - Nord America 541
AS - Asia 125
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.397
Nazione #
US - Stati Uniti d'America 534
IE - Irlanda 216
IT - Italia 140
SE - Svezia 119
DE - Germania 101
UA - Ucraina 64
IN - India 36
FI - Finlandia 35
CN - Cina 33
HK - Hong Kong 24
GB - Regno Unito 23
FR - Francia 20
SG - Singapore 9
TR - Turchia 9
CA - Canada 7
IR - Iran 7
VN - Vietnam 6
BE - Belgio 4
CH - Svizzera 3
RU - Federazione Russa 3
EU - Europa 1
GR - Grecia 1
JP - Giappone 1
RO - Romania 1
Totale 1.397
Città #
Dublin 214
Jacksonville 122
Dearborn 57
Piemonte 37
Ann Arbor 33
Wilmington 33
Chandler 28
Hong Kong 24
Lawrence 23
Princeton 23
Bremen 20
Beijing 19
Strasbourg 17
Milan 13
Andover 12
Ashburn 11
San Mateo 11
Turin 10
Kocaeli 9
Norwalk 8
Bari 6
Dong Ket 6
Novara 6
Singapore 6
Brussels 4
Houston 4
Kunming 4
Monmouth Junction 4
Mülheim 4
Nanjing 4
Woodbridge 4
Arcene 3
Helsinki 3
Leawood 3
Portland 3
Sacramento 3
Toronto 3
Winnipeg 3
Zanjan 3
Boardman 2
Bologna 2
Des Moines 2
Fairfield 2
Fuzhou 2
Grafing 2
Henderson 2
Rome 2
Zurich 2
Ardabil 1
Athens 1
Bangalore 1
Berlin 1
Biella 1
Bresso 1
Cambridge 1
Cento 1
Chongqing 1
Erding 1
Falkenstein 1
Hefei 1
Horia 1
Jinan 1
Lanzhou 1
Lausanne 1
Nepi 1
Ottawa 1
Perm 1
Seattle 1
Torino 1
Vercelli 1
Vigonza 1
Yaraichō 1
Totale 842
Nome #
Pharmaceutical combinations comprising estrogen receptor-beta agonists with platinum drugs or paclitaxel for treating ovarian cancer 87
PARP1 inhibition affects Pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1 81
SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells. 81
Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia 66
Targeting estrogen receptor beta (ERβ) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERβ expression and functionality 63
Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells 60
Expression and therapeutic significance of estrogen receptor beta (ERβ) in malignant pleural mesothelioma 56
Inhibition of the histone methyltransferase ezh2 enhances protumor monocyte recruitment in human mesothelioma spheroids 56
8-Prenylnaringenin inhibits epidermal growth factor-induced MCF-7 breast cancer cell proliferation by targeting phosphatidylinositol-3OH kinase activity 56
Estrogen receptor beta agonists for use in treating mesothelioma 53
Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma 52
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma 52
KDM6B histone demethylase is an epigenetic regulator of estrogen receptor β expression in human pleural mesothelioma 51
Coordinated sumoylation and ubiquitination modulate EGF induced EGR1 expression and stability 50
Estrogen receptor beta impacts on prognosis of human malignant mesothelioma 49
Therapies currently in phase II trials for malignant mesothelioma 49
Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity 49
ESTROGEN RECEPTOR ß ACTIVATION IMPAIRS MITOCHONDRIAL OXIDATIVE METABOLISM AND AFFECTS MALIGNANT MESOTHELIOMA CELL GROWTH IN VITRO AND IN VIVO 48
Estrogen receptor beta exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib 47
Flavonoid-induced autophagy in hormone-sensitive breast cancer cells 47
Expression and clinical implications of estrogen receptors in thoracic malignancies: a narrative review 46
Specific low-frequency electromagnetic fields induce expression of active KDM6B associated with functional changes in U937 cells 45
Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment 44
Transglutaminase 2 maintains a colorectal cancer stem phenotype by regulating epithelial-mesenchymal transition 42
CDKN2A determines mesothelioma cell fate to EZH2 inhibition 38
Unsymmetric cisplatin-based pt(Iv) conjugates containing a parp-1 inhibitor pharmacophore tested on malignant pleural mesothelioma cell lines 32
A Selective ALDH1A3 Inhibitor Impairs Mesothelioma 3-D Multicellular Spheroid Growth and Neutrophil Recruitment 22
Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma 10
The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CH3COO)Cl2(NH3)2(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake 9
Epigenetic Insights on PARP-1 Activity in Cancer Therapy 7
Melanoma Cells Inhibit iNKT Cell Functions via PGE2 and IDO1 4
Totale 1.452
Categoria #
all - tutte 7.122
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.122


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 0 1
2019/2020269 7 0 18 2 33 41 44 8 24 52 39 1
2020/2021186 24 5 22 1 19 3 23 1 27 26 27 8
2021/2022230 9 3 24 32 8 0 13 7 17 9 57 51
2022/2023464 25 17 27 10 27 44 5 29 224 8 28 20
2023/2024144 28 8 16 10 25 2 27 2 1 4 21 0
Totale 1.452